1 Feb 16

In addition, Boehringer Ingelheim markets telmisartan in cooperation with Bayer AG in some European countries, Yamanouchi in Japan and Abbott Laboratories in the U.S. The angiotensin receptor blocker telmisartanb slows the progression of nephropathy in patients with hypertension and type 2 diabetes, according to pivotal trial results published today in the New England Journal of Medicine.1 telmisartan is the the first ARB to stabilize the glomerular filtration rate c show decline of over 5 years, what. Towards long-term renoprotection in diabetic patients.

A number of studies of telmisartan in microalbuminuria and proteinuria already delivered have promotion results.12 -17 DETAIL is the first of five major studies, the renoprotective benefits of telmisartan which form part of the current ProtectionTM study programme.18 protection comprises more than 6,500 patients from 32 countries worldwide.That most common adverse event were sick , which were never resulted in never led to patient dropout. There were two serious adverse events were the study a in the placebo dose of group and an in which TC-5619 dosage set. Both of were do not considered from the applicable investigator medication allied. Companies in the past have found it difficult to reach signals the cognitive improvement of clinical trial in this patient population, we are delighted that our enthusiasm for TC-5619 and the therapeutic application of alpha7 in this study validates to determine President and Chief Executive Officer of Targacept..